PEG-MGF Reconstitution & BAC Water Research Guide
PEG-MGF, or pegylated mechano-growth factor, is an investigational peptide construct associated with the mechano-growth factor/MGF research literature. The underlying MGF and MGF-E-domain literature is predominantly preclinical or cell-based, while FDA states that it has not identified human exposure data for drug products containing PEG-MGF.
There is therefore no clinically established human PEG-MGF dose or authoritative universal BAC-water reconstitution volume to present as a recommendation. The concentration section below shows only the mathematics needed to understand how vial quantity and liquid volume determine mg/mL.
Research Snapshot
How Much BAC Water for PEG-MGF?
There is no authoritative universal BAC-water volume established for PEG-MGF. A reconstitution volume cannot be selected from a clinically established PEG-MGF dosing protocol because FDA has not identified human exposure data for drug products containing PEG-MGF.
For research concentration calculations, the relationship is straightforward: the amount of peptide represented by the vial stays constant, while increasing the liquid volume decreases the resulting concentration.
The examples below are mathematical concentration examples only. They are not manufacturer instructions, human doses, administration recommendations, or claims about standardized PEG-MGF vial sizes.
| Illustrative Vial Quantity | 1 mL | 2 mL | 2.5 mL | 3 mL | 5 mL |
|---|---|---|---|---|---|
| 1 mg | 1 mg/mL | 0.5 mg/mL | 0.4 mg/mL | 0.33 mg/mL | 0.2 mg/mL |
| 5 mg | 5 mg/mL | 2.5 mg/mL | 2 mg/mL | 1.67 mg/mL | 1 mg/mL |
| 10 mg | 10 mg/mL | 5 mg/mL | 4 mg/mL | 3.33 mg/mL | 2 mg/mL |
How Much BAC Water Should Be Added to 5 mg or 10 mg PEG-MGF?
There is no scientifically established single answer such as “add 1 mL” or “add 2 mL” for PEG-MGF. The correct mathematical result depends on the quantity stated on the actual research material and the liquid volume being evaluated.
How much BAC water for 5 mg PEG-MGF?
If a hypothetical label states 5 mg of material, different liquid volumes produce different mathematical concentrations:
- 1 mL → 5 mg/mL
- 2 mL → 2.5 mg/mL
- 2.5 mL → 2 mg/mL
- 3 mL → 1.67 mg/mL
- 5 mL → 1 mg/mL
These are calculations, not PEG-MGF instructions.
How much BAC water for 10 mg PEG-MGF?
If a hypothetical label states 10 mg of material:
- 1 mL → 10 mg/mL
- 2 mL → 5 mg/mL
- 2.5 mL → 4 mg/mL
- 3 mL → 3.33 mg/mL
- 5 mL → 2 mg/mL
These are calculations, not PEG-MGF instructions.
PEG-MGF & MGF Research Biology
MGF is associated with an IGF-1 splice-variant literature involving mechanically stressed muscle and tissue remodeling. Published work has investigated synthetic MGF E-domain peptides in cell and animal models.
PEG-MGF should not automatically be treated as equivalent to native MGF, an MGF E-domain peptide, or clinically approved IGF-1 products. Chemical modification, PEG attachment, molecular characterization, pharmacokinetics and biological behavior can materially change the research construct.
What Is PEG-MGF?
PEG-MGF refers to a pegylated form associated with mechano-growth factor (MGF). MGF is discussed in the scientific literature as an IGF-1 splice-variant-related molecule, particularly in the context of skeletal muscle and cellular responses to mechanical stress.
Published MGF research has also examined synthetic peptides corresponding to the unique E-domain of MGF. These research peptides should not be automatically equated with PEG-MGF. Pegylation introduces a polyethylene glycol component and creates a chemically modified research construct.
How PEG-MGF Relates to MGF Biology
MGF research originates from work on alternative IGF-1 transcripts and muscle responses to mechanical stress. The literature has investigated an E-domain-associated peptide for effects involving muscle progenitor cells, proliferation, survival and tissue-repair models.
Importantly, the mechanistic evidence is not equivalent to evidence that an administered PEG-MGF product produces a specific clinical outcome in humans.
What the literature actually supports
- MGF is associated with an IGF-1 splice-variant literature.
- Synthetic MGF E-domain peptides have been studied in cell models.
- Animal studies have investigated tissue-repair and cardiac applications.
- PEG-MGF itself has a substantially smaller evidence base than the broader MGF literature.
- FDA reports no identified human exposure data for drug products containing PEG-MGF.
What Is PEG-MGF Being Studied For?
The broader MGF/E-domain research literature has explored biological processes related to muscle progenitor-cell activity, cellular survival, tissue repair and cardiac injury models.
Muscle Biology
MGF-E peptide research has investigated muscle progenitor-cell proliferation, differentiation and fusion-related endpoints.
Tissue Repair
Experimental studies have investigated MGF E-domain peptides in tissue-repair and cardiac-injury models.
Cell Survival
Research has examined apoptosis-related and survival pathways in cultured cells and animal models.
Human Clinical Research
No clinically established human PEG-MGF dose has been identified. FDA's current compounding information states that it has not identified human exposure data on drug products containing PEG-MGF administered by any route.
This is a critical distinction because the existence of studies involving human-derived cells, exercise-associated endogenous MGF measurements, or animal models does not mean that PEG-MGF has been administered to humans in a controlled clinical trial.
Doses Studied in Published Research
Because PEG-MGF does not have an established human clinical dosing literature, this table deliberately separates studies of related MGF constructs from PEG-MGF itself.
| Study | Model / Population | Dose Studied | Route / Method | Frequency / Duration | Key Finding |
|---|---|---|---|---|---|
| Kandalla et al., 2011 | Primary human muscle-cell cultures | Experimental peptide concentration reported in full study | Cell culture | In-vitro experiment | MGF-E peptide affected proliferation/fusion-related endpoints. |
| Peña et al., 2015 | Mice following myocardial infarction | Experimental MGF E-domain peptide delivery | Localized intramuscular biomaterial delivery | Animal study | Investigated cardiac remodeling and functional outcomes after myocardial injury. |
| Sustained MGF delivery study, 2014 | Human mesenchymal stem cells and rat cardiac myocytes | Experimental MGF peptide loading | PEG-DMA microrod delivery system | Sustained local release | Studied stem-cell migration and protection from apoptosis. |
| PEG-MGF | Humans | No established clinical dose identified | No validated human administration protocol identified | No established clinical schedule | FDA reports no identified human exposure data for drug products containing PEG-MGF. |
Preclinical Research
The strongest part of the broader MGF literature is preclinical. Researchers have investigated synthetic MGF E-domain peptides in human muscle-cell cultures and in animal models.
Human-cell research
Kandalla and colleagues studied an MGF-E peptide in primary human muscle-cell cultures. The work examined proliferation, differentiation and fusion-related cellular behavior rather than administering PEG-MGF to human participants.
Animal research
Other studies investigated synthetic MGF E-domain peptides in mice and other experimental systems, including cardiac injury and tissue-repair models.
PEG-MGF Research Reconstitution & Concentration
The mathematical relationship between a stated vial quantity and liquid volume is independent of whether the compound is PEG-MGF, MGF-E, or another peptide.
Worked mathematical example: hypothetical 5 mg label
| Liquid Volume | Calculation | Resulting Concentration |
|---|---|---|
| 1 mL | 5 mg ÷ 1 mL | 5 mg/mL |
| 2 mL | 5 mg ÷ 2 mL | 2.5 mg/mL |
| 2.5 mL | 5 mg ÷ 2.5 mL | 2 mg/mL |
| 5 mL | 5 mg ÷ 5 mL | 1 mg/mL |
Worked mathematical example: hypothetical 10 mg label
| Liquid Volume | Calculation | Resulting Concentration |
|---|---|---|
| 1 mL | 10 mg ÷ 1 mL | 10 mg/mL |
| 2 mL | 10 mg ÷ 2 mL | 5 mg/mL |
| 2.5 mL | 10 mg ÷ 2.5 mL | 4 mg/mL |
| 5 mL | 10 mg ÷ 5 mL | 2 mg/mL |
BAC Water vs. PEG-MGF Concentration
More liquid produces a lower concentration. Less liquid produces a higher concentration, assuming the same total amount of compound.
- 5 mg ÷ 1 mL = 5 mg/mL
- 5 mg ÷ 2 mL = 2.5 mg/mL
- 5 mg ÷ 5 mL = 1 mg/mL
The total 5 mg quantity has not changed in any of these mathematical examples.
What BAC Water Does Not Tell You
- It does not establish a human dose.
- It does not establish clinical efficacy.
- It does not establish product stability.
- It does not prove a particular peptide is compatible with a particular diluent.
- It does not validate sterility or peptide purity.
For PEG-MGF, this distinction is especially important because FDA identifies concerns involving immunogenicity, peptide-related impurities and API characterization.
Research Limitations, Safety & Regulatory Status
FDA information on PEG-MGF
FDA's current information on certain bulk substances identifies Mechano Growth Factor Pegylated (PEG-MGF) as a substance for which compounded drugs may pose significant risks. FDA specifically notes potential concerns involving immunogenicity for certain routes, peptide-related impurities and API characterization.
FDA also states that it has not identified human exposure data for drug products containing PEG-MGF administered by any route and lacks important information regarding potential human safety issues.
FDA-approved use
No FDA-approved human therapeutic use for PEG-MGF has been identified in the authoritative sources reviewed for this page.
Clinically established dose
No clinically established human dose has been identified.
Important evidence distinctions
mg divided by mL produces a concentration.
Animal or cell findings do not establish human efficacy.
PEG-MGF has no established human clinical dose.
Explore More BacScience Research Resources
Frequently Asked Questions About PEG-MGF
How much BAC water should be added to PEG-MGF?
No universal PEG-MGF BAC-water volume has been established by an authoritative clinical or regulatory source reviewed for this page. Liquid volume changes concentration mathematically, but it does not establish an appropriate research or clinical protocol.
How much BAC water for 5 mg PEG-MGF?
There is no validated PEG-MGF-specific answer. As mathematics only, 5 mg divided by 1, 2, 2.5, 3 or 5 mL produces 5, 2.5, 2, 1.67 and 1 mg/mL respectively.
How much BAC water for 10 mg PEG-MGF?
There is no validated PEG-MGF-specific reconstitution volume. Mathematically, 10 mg divided by 1, 2, 2.5, 3 or 5 mL produces 10, 5, 4, 3.33 and 2 mg/mL respectively.
What is the PEG-MGF concentration formula?
Concentration (mg/mL) = total vial quantity (mg) ÷ liquid volume (mL).
Does adding more BAC water lower PEG-MGF concentration?
Yes, mathematically. If the total amount of peptide remains constant, increasing liquid volume decreases the amount represented per mL.
Is PEG-MGF FDA approved?
No FDA-approved human therapeutic use for PEG-MGF was identified in the authoritative sources reviewed. FDA currently identifies significant information gaps and potential safety concerns involving PEG-MGF compounded drugs.
Does MGF research prove PEG-MGF works in humans?
No. MGF and MGF E-domain research includes cell and animal studies, but those findings do not establish that PEG-MGF produces the same effects or is safe and effective in humans.
Is PEG-MGF the same as MGF-E?
They should not automatically be treated as identical. MGF-E refers to specific MGF E-domain peptide research constructs, whereas PEG-MGF refers to a pegylated MGF-associated construct.
Is there a clinically established PEG-MGF human dose?
No clinically established human dose has been identified. FDA reports no identified human exposure data for drug products containing PEG-MGF.
Can an animal-study dose be converted into a human dose?
Not by simply converting the units. Animal exposure, pharmacokinetics, route, formulation, species differences and safety margins all matter. BacScience does not convert preclinical PEG-MGF research parameters into human dosing recommendations.
Does BAC water determine how much PEG-MGF is in a vial?
No. In the mathematical model, the vial quantity is fixed and the liquid volume determines the resulting concentration. BAC water does not increase the total mass of PEG-MGF.
Scientific References
- U.S. Food and Drug Administration — Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. FDA's current information identifies PEG-MGF and describes concerns involving immunogenicity, peptide-related impurities, API characterization and lack of identified human exposure data.
- Kandalla PK, et al. — Mechano Growth Factor E peptide, derived from an isoform of IGF-1, activates human muscle progenitor cells. Mechanisms of Ageing and Development. 2011;132(4):154–162. PMID: 21354439.
- Peña JR, et al. — Localized delivery of mechano-growth factor E-domain peptide via polymeric microstructures improves cardiac function following myocardial infarction. Biomaterials. 2015;46:26–34. PMID: 25678113.
- Sustained delivery of MGF peptide from microrods attracts stem cells and reduces apoptosis of myocytes. PubMed. PMID: 24908137.
- Kuznetsova TV, et al. — Producing human mechano growth factor (MGF) in Escherichia coli. Protein Expression and Purification. 2008;58(1):70–77. PMID: 18068377.
- Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration. PubMed review. PMID: 20130113.
Scientific sources should be reviewed directly for the complete methods, experimental concentrations, limitations and context. This page does not reinterpret preclinical experimental conditions as human treatment instructions.
September 10, 2026
Scientific evidence, regulatory status, concentration mathematics and research-language compliance
Educational / research information — not medical advice